This fall and winter, communities will have a few new tools to help prevent respiratory syncytial virus (RSV) lower respiratory tract disease. In mid-July, the U.S. Food and Drug Administration approved Beyfortus (nirsevimab-alip), a one-dose immunization for all infants younger than eight months in their first RSV season, and children eight to 24 months of age with certain risk factors. Additionally, single dose RSV vaccines (Arexvy and Abrysvo) were approved for pregnant people and adults aged 60 and over to prevent severe RSV disease and hospitalization.

RSV, which causes acute respiratory infections, can have a significant impact on overall health. While most individuals experience mild symptoms, some, especially infants and seniors, are vulnerable to more dangerous lower respiratory tract diseases like pneumonia and bronchiolitis.

Every year, as many as 80,000 children under five years old are hospitalized due to RSV, according to the Centers for Disease Control and Prevention. For adults aged 65 and older, the CDC estimates that RSV is responsible for 60,000–160,000 hospitalizations and 6,000–10,000 deaths. In 2022, the number of older adults hospitalized with RSV-related health issues was 10 times higher than years prior to 2020.

About Beyfortus

Beyfortus is a laboratory-made protein that mirrors the immune system's ability to combat viruses. It is designed to target RSV. A single shot provides protection during the RSV season, which typically starts in the fall and peaks during winter.

Through a series of clinical trials, Beyfortus reduced the occurrence of RSV. One trial of term and late preterm infants, for example, resulted in a reduced risk of about 75%.

Looking Ahead

With experts predicting a surge in RSV cases this fall, the approval of RSV immunizations marks an important step in protecting infants, young children, pregnant people, and older adults. Immunizations remain a key pillar in safeguarding the health of our communities. These new preventative immunizations offer hope for preventing severe RSV-related complications.

Vaccinations at AltaMed

No matter your age, it’s important to stay protected. From RSV to COVID-19 to yearly flu shots, AltaMed can help you grow healthy. We also provide essential childhood, adolescent immunizations including the HPV vaccine for patients zero to 17 years of age.

Safety shouldn’t be complicated. Call us at (888) 499-9303 to schedule an appointment with your provider and stay on track of necessary vaccines.